[go: up one dir, main page]

DK0485563T3 - Polyether-substituted anti-tumor agents - Google Patents

Polyether-substituted anti-tumor agents

Info

Publication number
DK0485563T3
DK0485563T3 DK91910296.2T DK91910296T DK0485563T3 DK 0485563 T3 DK0485563 T3 DK 0485563T3 DK 91910296 T DK91910296 T DK 91910296T DK 0485563 T3 DK0485563 T3 DK 0485563T3
Authority
DK
Denmark
Prior art keywords
substituted
polyether
amino group
tumor agents
polyethylene glycol
Prior art date
Application number
DK91910296.2T
Other languages
Danish (da)
Inventor
Hans-J Sinn
Hans-Hermann Schrenk
Wolfgang Maier-Borst
Eckhard Friedrich
Georgi Graschew
Dieter Woehrle
Thomas Klenner
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4017439A external-priority patent/DE4017439C2/en
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK0485563T3 publication Critical patent/DK0485563T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Substances for treating or diagnosing tumours, with preferred concentration in the tumor, are characterized in that they have at least two phenolic hydroxyl and/or amino groups, at least one aliphatic amino group, or at least one phenolic hydroxyl and/or amino group and at least one aliphatic amino group, and these groups are substituted with polyethylene glycol chains, whose degree of polymerization n is 5 to 250 and whose terminal hydroxyl group is substituted by C1?-C12? alkyl ester or ether, each substance being substituted by at least two such polyethylene glycol chains.
DK91910296.2T 1990-05-30 1991-05-29 Polyether-substituted anti-tumor agents DK0485563T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4017439A DE4017439C2 (en) 1990-05-30 1990-05-30 Polyether-substituted tumor agents

Publications (1)

Publication Number Publication Date
DK0485563T3 true DK0485563T3 (en) 1995-03-20

Family

ID=6407498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910296.2T DK0485563T3 (en) 1990-05-30 1991-05-29 Polyether-substituted anti-tumor agents

Country Status (7)

Country Link
EP (1) EP0485563B1 (en)
JP (1) JP2640293B2 (en)
AT (1) ATE115864T1 (en)
DE (2) DE59103985D1 (en)
DK (1) DK0485563T3 (en)
ES (1) ES2068587T3 (en)
WO (1) WO1991018630A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
AU5085793A (en) * 1992-09-04 1994-03-29 General Hospital Corporation, The Biocompatible polymers containing diagnostic or therapeutic moieties
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
JPH08502300A (en) * 1992-10-14 1996-03-12 スターリング ウィンスロップ アイエヌシー． Therapeutic and diagnostic imaging compositions and methods
KR950703582A (en) * 1992-10-14 1995-09-20 조이스 이. 마임스 CHELATING POLYMERS
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
GB9408746D0 (en) * 1994-05-03 1994-06-22 Scotia Holdings Plc Tumour locallising photosensitising compounds
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
DE19706490C1 (en) 1997-02-19 1998-09-17 Deutsches Krebsforsch Process for the preparation of acid amides and for the metallization of compounds and use of the compounds produced by the processes
WO1998048845A1 (en) * 1997-04-29 1998-11-05 Nycomed Imaging As Method of demarcating tissue
JP5008793B2 (en) 1998-08-28 2012-08-22 デスティニー ファーマ リミテッド Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
GB0005855D0 (en) * 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
ITPD20030174A1 (en) * 2003-07-31 2003-10-29 Univ Padova POLYMERIC CONJUGATES FOR DIAGNOSTICS AND THERAPY
IL168184A (en) * 2005-04-21 2011-11-30 Univ Ariel Res & Dev Co Ltd Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy
US8853247B2 (en) 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
DE3546150A1 (en) * 1985-06-24 1987-01-22 Hoechst Ag MEMBRANE ANCHOR ACTIVE CONJUGATE, ITS PRODUCTION AND USE
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
IN165717B (en) * 1986-08-07 1989-12-23 Battelle Memorial Institute
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
JPH0751592B2 (en) * 1987-12-28 1995-06-05 帝人株式会社 Cyclotriphosphazene derivative
DE3809671A1 (en) * 1988-03-18 1989-09-28 Schering Ag PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
JPH0796558B2 (en) 1988-03-31 1995-10-18 協和醗酵工業株式会社 Modified polypeptide
WO1990015628A1 (en) 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
DE4017439C2 (en) * 1990-05-30 1994-06-23 Deutsches Krebsforsch Polyether-substituted tumor agents

Also Published As

Publication number Publication date
ATE115864T1 (en) 1995-01-15
ES2068587T3 (en) 1995-04-16
JP2640293B2 (en) 1997-08-13
EP0485563A1 (en) 1992-05-20
WO1991018630A1 (en) 1991-12-12
DE4139715C2 (en) 1994-08-11
EP0485563B1 (en) 1994-12-21
DE59103985D1 (en) 1995-02-02
JPH05501885A (en) 1993-04-08
DE4139715A1 (en) 1993-06-03

Similar Documents

Publication Publication Date Title
DK0485563T3 (en) Polyether-substituted anti-tumor agents
IT8026950A0 (en) PARTICLES OF SUBSTANCES SOLUBLE IN LIPOIDS AND BIOLOGICALLY ACTIVE COMPOSITIONS THAT CONTAIN THEM.
DE3885317D1 (en) Macromolecular platinum antitumor compounds.
ATE355848T1 (en) USE OF A PHOSPATIDYLSERINE/POLYPEPTIDE CONJUGATE TO PRODUCE AUTOIMMUNITY IN THE TREATMENT OF CANCER
NO166943C (en) ANALOGY PROCEDURE FOR PREPARING ENZYMESRESISTENT IMMUNO MODULATING PEPTIDES.
AR001267A1 (en) Carbon black treated method to prepare it polymeric formulation that includes device and shield that comprise said polymeric formulation
SE7612432L (en) COMPOSITION AND PROCEDURE FOR DISPERGING HIGH MOLECULAR FLOCKING POLYMERS IN WATER
BR8406642A (en) BISMALEIMIDE, "PREPRETABLE" RESIN COMPOSITION, PREPREG AND COMPOUND
AR222763A1 (en) COMPOSITIONS OF POLYMERS FOR THE TREATMENT OF DEPILED LEATHERS AND TANKED LEATHERS
ES2071616T3 (en) POLYMERS CONSISTING OF INSOLUBLE NUCLEUS IN ALCALI / SOLUBLE CRUST IN ALCALI AND COMPOSITIONS THEREOF.
SE7708687L (en) COMPOSITION WITH HIGHLY SOLID SUBSTANCES
DE69127175D1 (en) Antisense oligonucleotides for the treatment of cancer
FI830075A7 (en) Polymer compositions and their use as adhesives or in adhesives and other compositions.
GB1276594A (en) Reverse osmosis membranes
EP0215662A3 (en) Anti-tumor protease preparations
FI913391A0 (en) FOERFARANDE FOER DETEKTERING AV SMAOCELLCARCINOM OCH ANVAENDNING AV ACYLPEPTIDHYDROLAS OCH DENNA KODANDE SEKVENSER.
SE8000466L (en) POLYMERIC IMMUNE REGULATED AGENTS
DE69216113D1 (en) OIL AND FUEL OIL COMPOSITIONS
FI830523L (en) ANTI-INFLAMMATORY OCH / ELLER SMAERTA LINDRANDE 2,3-DIARYL-5-HALOTIOFENER
AT297332B (en) Process for increasing the molecular weight of high molecular weight linear polycondensates or their precursors
DE59108407D1 (en) Galactomannan derivatives for wrapping or embedding active pharmaceutical ingredients
ATE22899T1 (en) ANTITHROMBIN HEPARIN COMPLEX.
SE8601563D0 (en) MATERIAL MATERIAL, PROCEDURES FOR PREPARING IT AND USING IT
TR199800343T1 (en) Dirt-dissolving polymers made from polycarbonates.
ES2038239T3 (en) PROCEDURE FOR THE PREPARATION OF POLYMERS CONTAINING PERFLUOROPOLIETHERAL CHAINS USING TERTIARY AMINIC COMPOUNDS CONTAINING AT LEAST THREE ACTIVE HYDROGENS.